Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers.

Szczegóły
Abstrakt

Tytuł:: Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers.
Autorzy:: Wang J; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ma X; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ma Z; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ma Y; Department of Comprehensive Medicine, Beijing Shijingshan Hospital, Beijing, China.
Wang J; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Cao B; Department of Oncology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Źródło:: Frontiers in immunology [Front Immunol] 2022 Apr 13; Vol. 13, pp. 810539. Date of Electronic Publication: 2022 Apr 13 (Print Publication: 2022).
Typ publikacji:: Journal Article; Review; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Lausanne : Frontiers Research Foundation]
MeSH Terms:: Digestive System Neoplasms*/drug therapy
Immune Checkpoint Inhibitors*/therapeutic use
Biomarkers, Tumor/metabolism ; DNA Mismatch Repair ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy
References:: Science. 2020 Aug 21;369(6506):936-942. (PMID: 32820119)
Lancet. 2008 Feb 16;371(9612):569-78. (PMID: 18280327)
PLoS One. 2019 Apr 15;14(4):e0215393. (PMID: 30986253)
J Mol Diagn. 2017 Jan;19(1):84-91. (PMID: 27863258)
Mol Oncol. 2020 Sep;14(9):2096-2110. (PMID: 32502294)
Ann Oncol. 2019 Aug 1;30(8):1232-1243. (PMID: 31056702)
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):13-16. (PMID: 28069727)
Nat Biotechnol. 2022 Apr;40(4):499-506. (PMID: 34725502)
JAMA Oncol. 2020 Oct 1;6(10):1571-1580. (PMID: 32880601)
J Immunother Cancer. 2019 Jul 23;7(1):193. (PMID: 31337439)
JAMA Oncol. 2019 Apr 01;5(4):546-550. (PMID: 30570649)
Science. 2015 Apr 3;348(6230):124-8. (PMID: 25765070)
Ann Oncol. 2019 Jul 1;30(7):1096-1103. (PMID: 31038663)
Nat Genet. 2020 Sep;52(9):919-930. (PMID: 32719515)
J Clin Oncol. 2019 Feb 1;37(4):318-327. (PMID: 30557521)
Ther Adv Med Oncol. 2021 Jan 31;13:1758835921988996. (PMID: 33613701)
Lancet. 2018 May 26;391(10135):2128-2139. (PMID: 29754777)
Lancet. 2017 Jun 24;389(10088):2492-2502. (PMID: 28434648)
Br J Cancer. 2016 Jul 26;115(3):273-80. (PMID: 27380134)
Nat Rev Clin Oncol. 2021 Jun;18(6):345-362. (PMID: 33580222)
Oncoimmunology. 2020 Feb 26;9(1):1731942. (PMID: 32158624)
Lancet Oncol. 2018 Jul;19(7):940-952. (PMID: 29875066)
J Immunother Cancer. 2019 Feb 27;7(1):57. (PMID: 30813970)
Cell. 2021 Feb 4;184(3):596-614.e14. (PMID: 33508232)
J Immunother Cancer. 2021 Jul;9(7):. (PMID: 34315821)
Lancet Oncol. 2020 Oct;21(10):1353-1365. (PMID: 32919526)
N Engl J Med. 2015 Jun 25;372(26):2509-20. (PMID: 26028255)
Ann Transl Med. 2019 Nov;7(22):640. (PMID: 31930041)
Gut. 2022 Mar;71(3):457-466. (PMID: 34253574)
J Natl Cancer Inst. 2018 Mar 1;110(3):316-320. (PMID: 29155997)
JAMA Oncol. 2019 Oct 1;5(10):1504-1506. (PMID: 31415061)
Ann Oncol. 2021 May;32(5):661-672. (PMID: 33736924)
J Hematol Oncol. 2020 May 11;13(1):47. (PMID: 32393323)
Pathology. 2020 Feb;52(2):228-235. (PMID: 31685233)
Cell. 2019 Sep 19;179(1):219-235.e21. (PMID: 31522890)
Surg Today. 2020 Nov;50(11):1486-1495. (PMID: 32542414)
Nat Cancer. 2020 Sep;1(9):873-881. (PMID: 35121950)
Theranostics. 2018 Nov 10;8(20):5690-5702. (PMID: 30555574)
BMC Cancer. 2019 Oct 21;19(1):974. (PMID: 31638948)
Gut. 2017 May;66(5):794-801. (PMID: 26801886)
Sci Transl Med. 2021 Aug 25;13(608):. (PMID: 34433638)
Clin Cancer Res. 2016 May 1;22(9):2177-82. (PMID: 26667490)
Cancer Immunol Res. 2017 Jun;5(6):480-492. (PMID: 28522460)
Nature. 2014 Sep 11;513(7517):202-9. (PMID: 25079317)
Cancer Immunol Res. 2018 Sep;6(9):990-1000. (PMID: 30181337)
Pathol Res Pract. 2021 Oct;226:153605. (PMID: 34530257)
J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33462141)
Nat Med. 2018 Sep;24(9):1449-1458. (PMID: 30013197)
J Clin Oncol. 2020 Jan 1;38(1):11-19. (PMID: 31725351)
Oncoimmunology. 2018 Mar 6;7(7):e1438111. (PMID: 29900038)
Clin Cancer Res. 2019 Apr 1;25(7):2116-2126. (PMID: 30373752)
Head Neck. 2020 Oct;42(10):3018-3030. (PMID: 32567746)
J Clin Oncol. 2020 Jan 1;38(1):1-10. (PMID: 31682550)
Science. 2020 May 29;368(6494):973-980. (PMID: 32467386)
Lancet. 2019 Nov 23;394(10212):1915-1928. (PMID: 31679945)
J Clin Oncol. 2018 Mar 10;36(8):773-779. (PMID: 29355075)
Nature. 2021 Apr;592(7854):450-456. (PMID: 33762733)
Ann Oncol. 2016 Mar;27(3):409-16. (PMID: 26681673)
Front Immunol. 2021 Aug 31;12:651634. (PMID: 34531847)
Science. 2016 Mar 25;351(6280):1463-9. (PMID: 26940869)
Science. 2018 Oct 12;362(6411):. (PMID: 30309915)
Mol Cancer. 2021 Feb 23;20(1):37. (PMID: 33622313)
Science. 2020 Sep 18;369(6510):1481-1489. (PMID: 32792462)
Immunotherapy. 2016;8(1):1-3. (PMID: 26643016)
Oncotarget. 2016 May 31;7(22):32925-32. (PMID: 27147580)
Clin Cancer Res. 2021 Mar 15;27(6):1631-1640. (PMID: 33355200)
Lancet Oncol. 2018 Jun;19(6):737-746. (PMID: 29778737)
Gan To Kagaku Ryoho. 2020 Apr;47(4):725-727. (PMID: 32389997)
Science. 2018 Jan 5;359(6371):32-34. (PMID: 29302001)
Clin Cancer Res. 2019 Apr 1;25(7):2021-2023. (PMID: 30617138)
Liver Int. 2019 Nov;39(11):2184-2189. (PMID: 31400295)
Nat Med. 2019 Jan;25(1):141-151. (PMID: 30420753)
Theranostics. 2017 Aug 22;7(14):3585-3594. (PMID: 28912897)
Lancet Oncol. 2017 Sep;18(9):1182-1191. (PMID: 28734759)
J Thorac Oncol. 2020 Apr;15(4):556-567. (PMID: 31843683)
Oncotarget. 2018 Oct 02;9(77):34520-34527. (PMID: 30349646)
Ann Oncol. 2019 Sep 1;30(9):1479-1486. (PMID: 31236579)
Nat Commun. 2021 Feb 1;12(1):729. (PMID: 33526794)
Oncologist. 2020 Aug;25(8):669-679. (PMID: 31943525)
Ann Clin Lab Sci. 2018 Nov;48(6):695-706. (PMID: 30610038)
JAMA Oncol. 2019 Jul 01;5(7):1043-1047. (PMID: 31021392)
Histopathology. 2022 Jan;80(2):397-406. (PMID: 34496080)
JAMA Oncol. 2018 May 10;4(5):e180013. (PMID: 29543932)
Mol Cancer Ther. 2017 Nov;16(11):2598-2608. (PMID: 28835386)
J Oral Pathol Med. 2021 Oct;50(9):864-873. (PMID: 34157159)
Cancer Lett. 2020 Mar 31;473:148-155. (PMID: 31911080)
World J Gastroenterol. 2014 May 21;20(19):5583-93. (PMID: 24914318)
Science. 2018 Feb 2;359(6375):582-587. (PMID: 29217585)
Nat Med. 2016 Nov;22(11):1342-1350. (PMID: 27694933)
Science. 2017 Jul 28;357(6349):409-413. (PMID: 28596308)
Gastric Cancer. 2020 Jan;23(1):95-104. (PMID: 31451991)
J Immunother Cancer. 2021 May;9(5):. (PMID: 33972389)
Lancet Oncol. 2020 Jun;21(6):832-842. (PMID: 32416073)
Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):95-100. (PMID: 29576277)
Contributed Indexing:: Keywords: biomarker; digestive system cancers; immune check inhibitor (ICI); immunotherapy; predict therapeutic effectiveness
Substance Nomenclature:: 0 (Biomarkers, Tumor)
0 (Immune Checkpoint Inhibitors)
0 (Immunologic Factors)
Entry Date(s):: Date Created: 20220502 Date Completed: 20220503 Latest Revision: 20220716
Update Code:: 20240104
PubMed Central ID:: PMC9043345
DOI:: 10.3389/fimmu.2022.810539
PMID:: 35493526
: Czasopismo naukowe

Full Text Finder

Immunotherapy represented by immune checkpoint inhibitors has gradually entered a new era of precision medicine. In view of the limited clinical benefits of immunotherapy in patients with digestive system cancers, as well as the side-effects and high treatment costs, development of biomarkers to predict the efficacy of immune therapy is a key imperative. In this article, we review the available evidence of the value of microsatellite mismatch repair, tumor mutation burden, specific mutated genes or pathways, PD-L1 expression, immune-related adverse reactions, blood biomarkers, and patient-related biomarkers in predicting the efficacy of immunotherapy against digestive system cancers. Establishment of dynamic personalized prediction models based on multiple biomarkers is a promising area for future research.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Wang, Ma, Ma, Ma, Wang and Cao.)

Informacja